• About
    • Viatris in Europe
      • Unlocking European patients access to medicines
    • Viatris' Manufacturing Footprint
    • Sustainability at Viatris
    • Memberships and Partnerships
  • Policy
    • Policy for Access
      • Preserving Patients Access to Off-Patent Medicines
      • Protecting Access to Essential Antibiotics
      • VAM: Improving Patient Outcomes with Existing Medicines
      • Securing Access to Critical Medicines
    • Green Deal
      • Environmental Stewardship
    • Strategic Autonomy & Industrial Strategy
      • Investing in Supply Resilience to Secure Access
      • Best Procurement Practices
    • Digital Strategy
      • European Health Data Space
  • Public Health
    • AMR
    • Tackling Noncommunicable Diseases
    • Advancing Access to Anaphylaxis Treatment
    • Influenza
    • Infectious Diseases
    • COVID-19
  • Conversation
Show Menu

Infectious Diseases

Continued partnership is needed in the fight against infectious diseases like HIV and tuberculosis, which remain public health concerns in Europe.

In recent years, the burden of infectious diseases has reduced or remained stable in Europe, thanks to strong commitments by the EU, aggressive targets, and cooperation among stakeholders. Still, diseases like HIV and tuberculosis remain public health concerns in Europe and around the world and are the focus of the UN’s Sustainable Development Goal 3.3. At Viatris, we commend the EU’s solidarity in addressing the burden of HIV and TB globally and call for continued partnership in the global fight against infectious diseases.

Infectious Diseases

  • HIV
  • Tuberculosis

Tuberculosis

 

Tuberculosis (TB) is the leading infectious killer aside from COVID-19. More than 1.5 million people die annually from TB, while an estimated 10 million people worldwide were newly diagnosed. An increasing number of these cases are multi-drug resistant TB (MDR-TB), which is much more difficult to treat.3 Due to the progression of antimicrobial resistance, the burden of MDR-TB is projected to become significantly worse, taking millions of lives a year by 2050.4

As the largest producer of medicines to treat HIV, and given the significant co-infection of HIV and TB, we realized we have a powerful platform to help those living with TB today and prepare for the future impact of MDR-TB. In collaboration with TB Alliance, Viatris has made available the first drug approved to treat extensively drug resistant TB (XDR-TB) or MDR/RR-TB that is treatment-intolerant or non-responsive. This medicine represents one of the few innovations in TB treatment in the last half century.

TB remains a major public health challenge in Europe. In 2021, we made drug-resistant TB treatment available in 22 European countries, via a partnership with Tanner Pharmaceuticals. The treatment was approved by the European Medicines Agency to be used as part of a combination regimen to treat XDR-TB and MDR/RR-TB.

Learn more about our progress in TB care

World TB Day 2022

March 24 is World TB Day, a day dedicated to acknowledging the incredible progress that has been made in the fight against tuberculosis (TB).

TB Courage

See Besik’s story of TB Courage - thanks to our partners at TB Alliance

3. World Health Organization
4. Antimicrobial Resistance Industry Alliance

Leaving the Viatris site

You are now leaving the Viatris page for a Viatris affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Viatris affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Continue
Cancel

Viatris Policy and Government Affairs

  • Privacy Notice
  • Cookie Notice
  • Terms of Use
  • Contact Us
  • Privacy Notice
    • Dutch
    • French
  • Cookie Notice
    • Dutch
    • French
  • Terms of Use
  • Contact Us
© 2025 Viatris
Created on: 6/25/2021
Updated on: 2/7/2024